APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-acting DPP-4 Inhibitor Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting DPP-4 Inhibitor Drug Market Analysis and Forecast 2026-2032

Report ID 174008760227 December 2025192 pages

Choose your research edition.

Industry ResearchLong-acting DPP-4 Inhibitor Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting DPP-4 Inhibitor Drug Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Long-acting DPP-4 Inhibitor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting DPP-4 Inhibitor Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting DPP-4 Inhibitor Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Long-acting DPP-4 Inhibitor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting DPP-4 Inhibitor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Long-acting DPP-4 Inhibitor Drug include Easton Biopharmaceuticals, Takeda Pharmaceutical, Merck & Co, Kelun Pharmaceutical, Haisco Pharmaceutical, Beacon Pharma, Baiji Dichang Pharmaceutical and Furiex, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Long-acting DPP-4 Inhibitor Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting DPP-4 Inhibitor Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Long-acting DPP-4 Inhibitor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting DPP-4 Inhibitor Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting DPP-4 Inhibitor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Long-acting DPP-4 Inhibitor Drug revenue, projected growth trends, production technology, application and end-user industry.

Long-acting DPP-4 Inhibitor Drug Segment by Company

Easton Biopharmaceuticals

Takeda Pharmaceutical

Merck & Co

Kelun Pharmaceutical

Haisco Pharmaceutical

Beacon Pharma

Baiji Dichang Pharmaceutical

Furiex

Long-acting DPP-4 Inhibitor Drug Segment by Type

Weekly

Biweekly

Long-acting DPP-4 Inhibitor Drug Segment by Application

Hospital

Clinic

Others

Long-acting DPP-4 Inhibitor Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting DPP-4 Inhibitor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting DPP-4 Inhibitor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting DPP-4 Inhibitor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Long-acting DPP-4 Inhibitor Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Long-acting DPP-4 Inhibitor Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting DPP-4 Inhibitor Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Weekly Major Player Table 3. Biweekly Major Player Table 4. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Others Major Player Table 8. Long-acting DPP-4 Inhibitor Drug Industry Trends Table 9. Long-acting DPP-4 Inhibitor Drug Industry Drivers Table 10. Long-acting DPP-4 Inhibitor Drug Industry Opportunities and Challenges Table 11. Long-acting DPP-4 Inhibitor Drug Industry Restraints Table 12. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region (2021-2026) Table 15. Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region (2027-2032) Table 17. Global Long-acting DPP-4 Inhibitor Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2021-2026) Table 19. Global Long-acting DPP-4 Inhibitor Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Long-acting DPP-4 Inhibitor Drug Key Players Headquarters & Area Served Table 21. Global Long-acting DPP-4 Inhibitor Drug Players, Product Type & Application Table 22. Global Long-acting DPP-4 Inhibitor Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Long-acting DPP-4 Inhibitor Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2021-2026) Table 29. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2027-2032) Table 30. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2021-2026) Table 34. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2027-2032) Table 35. Easton Biopharmaceuticals Company Information Table 36. Easton Biopharmaceuticals Business Overview Table 37. Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 39. Easton Biopharmaceuticals Recent Development Table 40. Takeda Pharmaceutical Company Information Table 41. Takeda Pharmaceutical Business Overview Table 42. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 44. Takeda Pharmaceutical Recent Development Table 45. Merck & Co Company Information Table 46. Merck & Co Business Overview Table 47. Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 49. Merck & Co Recent Development Table 50. Kelun Pharmaceutical Company Information Table 51. Kelun Pharmaceutical Business Overview Table 52. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 54. Kelun Pharmaceutical Recent Development Table 55. Haisco Pharmaceutical Company Information Table 56. Haisco Pharmaceutical Business Overview Table 57. Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 59. Haisco Pharmaceutical Recent Development Table 60. Beacon Pharma Company Information Table 61. Beacon Pharma Business Overview Table 62. Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 64. Beacon Pharma Recent Development Table 65. Baiji Dichang Pharmaceutical Company Information Table 66. Baiji Dichang Pharmaceutical Business Overview Table 67. Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 69. Baiji Dichang Pharmaceutical Recent Development Table 70. Furiex Company Information Table 71. Furiex Business Overview Table 72. Furiex Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio Table 74. Furiex Recent Development Table 75. North America Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 76. North America Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 77. North America Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 78. North America Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 79. North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (US$ Million) & (2027-2032) Table 82. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 83. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 84. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 85. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 86. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026) & (US$ Million) Table 88. Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (US$ Million) & (2027-2032) Table 89. China Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 90. China Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 91. China Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 92. China Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 93. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 94. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 95. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 96. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Region (US$ Million) & (2021-2026) Table 99. Asia Long-acting DPP-4 Inhibitor Drug Revenue by Region (US$ Million) & (2027-2032) Table 100. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (US$ Million) & (2027-2032) Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Long-acting DPP-4 Inhibitor Drug Image Figure 2. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting DPP-4 Inhibitor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Weekly Image Figure 5. Biweekly Image Figure 6. Global Long-acting DPP-4 Inhibitor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Long-acting DPP-4 Inhibitor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Long-acting DPP-4 Inhibitor Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Long-acting DPP-4 Inhibitor Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Long-acting DPP-4 Inhibitor Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Long-acting DPP-4 Inhibitor Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032) Figure 24. North America Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032) Figure 25. North America Long-acting DPP-4 Inhibitor Drug Revenue Share by Country (2021-2032) Figure 26. United States Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032) Figure 31. Europe Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032) Figure 32. Europe Long-acting DPP-4 Inhibitor Drug Revenue Share by Country (2021-2032) Figure 33. Germany Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032) Figure 43. China Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032) Figure 44. Asia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032) Figure 46. Asia Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032) Figure 47. Asia Long-acting DPP-4 Inhibitor Drug Revenue Share by Region (2021-2032) Figure 48. Japan Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Long-acting DPP-4 Inhibitor Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Long-acting DPP-4 Inhibitor Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Weekly
  • Biweekly
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Easton Biopharmaceuticals
  • Takeda Pharmaceutical
  • Merck & Co
  • Kelun Pharmaceutical
  • Haisco Pharmaceutical
  • Beacon Pharma
  • Baiji Dichang Pharmaceutical
  • Furiex

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting DPP-4 Inhibitor Drug Market by Type
  3. 1.2.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Weekly
  5. 1.2.3 Biweekly
  6. 1.3 Long-acting DPP-4 Inhibitor Drug Market by Application
  7. 1.3.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Long-acting DPP-4 Inhibitor Drug Market Dynamics
  1. 2.1 Long-acting DPP-4 Inhibitor Drug Industry Trends
  2. 2.2 Long-acting DPP-4 Inhibitor Drug Industry Drivers
  3. 2.3 Long-acting DPP-4 Inhibitor Drug Industry Opportunities and Challenges
  4. 2.4 Long-acting DPP-4 Inhibitor Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Long-acting DPP-4 Inhibitor Drug Market Perspective (2021-2032)
  2. 3.2 Global Long-acting DPP-4 Inhibitor Drug Growth Trends by Region
  3. 3.2.1 Global Long-acting DPP-4 Inhibitor Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Long-acting DPP-4 Inhibitor Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Long-acting DPP-4 Inhibitor Drug Revenue by Players
  2. 4.1.1 Global Long-acting DPP-4 Inhibitor Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Long-acting DPP-4 Inhibitor Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting DPP-4 Inhibitor Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Long-acting DPP-4 Inhibitor Drug Key Players Headquarters & Area Served
  7. 4.4 Global Long-acting DPP-4 Inhibitor Drug Players, Product Type & Application
  8. 4.5 Global Long-acting DPP-4 Inhibitor Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Long-acting DPP-4 Inhibitor Drug Market CR5 and HHI
  11. 4.6.3 2025 Long-acting DPP-4 Inhibitor Drug Tier 1, Tier 2, and Tier 3
5 Long-acting DPP-4 Inhibitor Drug Market Size by Type
  1. 5.1 Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 5.3 Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Type (2021-2032)
6 Long-acting DPP-4 Inhibitor Drug Market Size by Application
  1. 6.1 Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  3. 6.3 Global Long-acting DPP-4 Inhibitor Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Easton Biopharmaceuticals
  2. 7.1.1 Easton Biopharmaceuticals Company Information
  3. 7.1.2 Easton Biopharmaceuticals Business Overview
  4. 7.1.3 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Easton Biopharmaceuticals Long-acting DPP-4 Inhibitor Drug Product Portfolio
  6. 7.1.5 Easton Biopharmaceuticals Recent Developments
  7. 7.2 Takeda Pharmaceutical
  8. 7.2.1 Takeda Pharmaceutical Company Information
  9. 7.2.2 Takeda Pharmaceutical Business Overview
  10. 7.2.3 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  12. 7.2.5 Takeda Pharmaceutical Recent Developments
  13. 7.3 Merck & Co
  14. 7.3.1 Merck & Co Company Information
  15. 7.3.2 Merck & Co Business Overview
  16. 7.3.3 Merck & Co Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co Long-acting DPP-4 Inhibitor Drug Product Portfolio
  18. 7.3.5 Merck & Co Recent Developments
  19. 7.4 Kelun Pharmaceutical
  20. 7.4.1 Kelun Pharmaceutical Company Information
  21. 7.4.2 Kelun Pharmaceutical Business Overview
  22. 7.4.3 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Kelun Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  24. 7.4.5 Kelun Pharmaceutical Recent Developments
  25. 7.5 Haisco Pharmaceutical
  26. 7.5.1 Haisco Pharmaceutical Company Information
  27. 7.5.2 Haisco Pharmaceutical Business Overview
  28. 7.5.3 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Haisco Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  30. 7.5.5 Haisco Pharmaceutical Recent Developments
  31. 7.6 Beacon Pharma
  32. 7.6.1 Beacon Pharma Company Information
  33. 7.6.2 Beacon Pharma Business Overview
  34. 7.6.3 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Beacon Pharma Long-acting DPP-4 Inhibitor Drug Product Portfolio
  36. 7.6.5 Beacon Pharma Recent Developments
  37. 7.7 Baiji Dichang Pharmaceutical
  38. 7.7.1 Baiji Dichang Pharmaceutical Company Information
  39. 7.7.2 Baiji Dichang Pharmaceutical Business Overview
  40. 7.7.3 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Baiji Dichang Pharmaceutical Long-acting DPP-4 Inhibitor Drug Product Portfolio
  42. 7.7.5 Baiji Dichang Pharmaceutical Recent Developments
  43. 7.8 Furiex
  44. 7.8.1 Furiex Company Information
  45. 7.8.2 Furiex Business Overview
  46. 7.8.3 Furiex Long-acting DPP-4 Inhibitor Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Furiex Long-acting DPP-4 Inhibitor Drug Product Portfolio
  48. 7.8.5 Furiex Recent Developments
8 North America
  1. 8.1 North America Long-acting DPP-4 Inhibitor Drug Revenue (2021-2032)
  2. 8.2 North America Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032)
  5. 8.3 North America Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032)
  9. 8.5 North America Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Long-acting DPP-4 Inhibitor Drug Revenue by Country
  11. 8.6.1 North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Long-acting DPP-4 Inhibitor Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting DPP-4 Inhibitor Drug Revenue (2021-2032)
  2. 9.2 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country
  11. 9.6.1 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Long-acting DPP-4 Inhibitor Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Long-acting DPP-4 Inhibitor Drug Revenue (2021-2032)
  2. 10.2 China Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032)
  5. 10.3 China Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032)
  9. 10.5 China Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting DPP-4 Inhibitor Drug Revenue (2021-2032)
  2. 11.2 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Country
  11. 11.6.1 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Long-acting DPP-4 Inhibitor Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue (2021-2032)
  2. 12.2 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country
  11. 12.6.1 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Long-acting DPP-4 Inhibitor Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst